NasdaqGM - Nasdaq Real Time Price USD

Bionomics Limited (BNOX)

0.9301 +0.0026 (+0.28%)
As of 12:58 PM EDT. Market Open.
Currency in AUD All numbers in thousands
Download
Breakdown
TTM
6/30/2023
6/30/2022
6/30/2021
6/30/2020
Total Revenue
22.0470
22.0470
263.6340
--
46.6620
Gross Profit
--
--
--
--
46.6620
Operating Expense
30,918.2590
31,996.6020
21,605.1630
11,922.2800
9,061.3160
Operating Income
-30,896.2120
-31,974.5550
-21,341.5290
-11,922.2800
-9,014.6540
Net Non Operating Interest Income Expense
472.1750
450.4960
-34.2960
-1,438.1290
-1,788.0980
Other Income Expense
-792.9060
-529.6900
-575.3410
4,475.9450
4,776.1650
Pretax Income
-31,216.9430
-32,053.7490
-21,951.1660
-8,884.4640
-6,026.5870
Tax Provision
-209.4940
-206.7920
-191.8080
-187.4270
-207.6120
Net Income Common Stockholders
-31,007.4490
-31,846.9570
-21,759.3580
-8,697.0370
-7,118.2880
Diluted NI Available to Com Stockholders
-31,007.4490
-31,846.9570
-21,759.3580
-8,697.0370
-7,118.2880
Basic EPS
-3.06
-3.60
-3.60
-2.02
-2.22
Diluted EPS
-3.06
-3.60
-3.60
-2.02
-2.22
Basic Average Shares
9,151.1490
8,159.6410
7,518.6150
4,333.0060
3,208.6410
Diluted Average Shares
9,151.1490
8,159.6410
7,518.6150
4,333.0060
3,208.6410
Rent Expense Supplemental
221.1310
220.3440
262.4400
1,272.4140
1,180.4820
Total Expenses
30,918.2590
31,996.6020
21,605.1630
11,922.2800
9,061.3160
Net Income from Continuing & Discontinued Operation
-31,007.4490
-31,846.9570
-21,759.3580
-8,697.0370
-7,118.2880
Normalized Income
-29,594.7068
-31,320.6842
-21,182.4286
-12,879.8261
-10,237.2199
Interest Income
503.8020
479.7260
9.8690
5.7560
58.3690
Interest Expense
21.9260
21.2780
26.8720
1,174.3390
1,794.3220
Net Interest Income
472.1750
450.4960
-34.2960
-1,438.1290
-1,788.0980
EBIT
-31,195.0170
-32,032.4710
-21,924.2940
-7,710.1250
-4,232.2650
EBITDA
-31,195.0170
-30,875.4790
-20,814.8820
-6,009.2470
-1,788.8790
Reconciled Depreciation
--
1,156.9920
1,109.4120
1,700.8780
2,443.3860
Net Income from Continuing Operation Net Minority Interest
-31,007.4490
-31,846.9570
-21,759.3580
-8,697.0370
-5,818.9750
Total Unusual Items Excluding Goodwill
-1,422.2870
-529.6900
-582.0150
4,272.9310
4,575.8810
Total Unusual Items
-1,422.2870
-529.6900
-582.0150
4,272.9310
4,575.8810
Normalized EBITDA
-29,772.7300
-30,345.7890
-20,232.8670
-10,282.1780
-6,364.7600
Tax Rate for Calcs
0.0000
0.0000
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
-9.5448
-3.4172
-5.0856
90.1419
157.6361
6/30/2020 - 12/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

OKYO OKYO Pharma Limited
1.4650
-1.01%
 
KPRX Kiora Pharmaceuticals, Inc.
0.4946
-2.93%
 
RNXT RenovoRx, Inc.
1.4550
+1.75%
 
CING Cingulate Inc.
0.8391
+6.44%
 
INM InMed Pharmaceuticals Inc.
0.2739
+4.07%
 
ORGS Orgenesis Inc.
0.6298
+3.25%
 
PMVP PMV Pharmaceuticals, Inc.
2.0800
-2.35%
 
BRTX BioRestorative Therapies, Inc.
1.3700
+4.58%
 
DRMA Dermata Therapeutics, Inc.
0.3402
-10.47%
 
CYTO Altamira Therapeutics Ltd.
1.4410
-2.64%